Pulmonary Vascular Disease News

Use of an automated, text message-based mobile health intervention helped to increase physical activity levels in adults with pulmonary arterial hypertension, researchers reported in Chest.

The Healio Editors have compiled a list of recent articles about pulmonary hypertension in recognition of World Pulmonary Hypertension Day.

This week, the question of whether we’ll need COVID-19 booster shots; the ACIP recommends resuming use of the J&J COVID-19 vaccine; humans in the UK transmitted SARS-CoV-2 to their cats; an NBA study shows that persistent positive cases do not transmit COVID-19 after recovery; and neurological symptoms with COVID-19 serve as an ‘important predictor’ of poor outcomes.

A new study highlights the clinical differences and outcomes of methamphetamine-associated pulmonary artery hypertension compared with idiopathic PAH, including less favorable hemodynamics and regional variation.

This week, the benefits of using telemedicine to address sleep disorders and provide cystic fibrosis care; rituximab may be an effective adjuvant treatment for systemic sclerosis and PAH; the FDA says facilities should move away from crisis capacity conservation measures; and researchers call for standardization to identify and categorize environmental exposures when assessing interstitial lung disease progression.

B-cell depletion with rituximab was safe and may be a potentially effective treatment for patients with systemic sclerosis-associated pulmonary arterial hypertension, researchers reported.

Among veterans hospitalized at Veterans Affairs facilities, patients with COVID-19 are at elevated risk for venous thromboembolism, according to a study published in the American Heart Journal.

The FDA approved inhaled treprostinil for the treatment of patients with pulmonary hypertension associated with interstitial lung disease, according to a press release from United Therapeutics.

Treatment with sotatercept for 24 weeks resulted in a reduction in pulmonary vascular resistance among patients with pulmonary arterial hypertension therapy, according to results of the PULSAR trial.

In a study of patients with acute pulmonary embolism treated at 740 U.S. hospitals, fewer than 5% were discharged home from the ED, researchers reported in Academic Emergency Medicine.